The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer
Background. The efficacy of squamous cell carcinoma antigen (SCC‐Ag) in laryngeal cancer to predict those patients who will relapse after primary treatment (surgery or radiotherapy) and its utility to detect relapses early and thereby increase salvage rates and cure were assesed. Methods. Sixty heal...
Gespeichert in:
| Veröffentlicht in: | Cancer 1995-09, Vol.76 (5), p.758-764 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 764 |
|---|---|
| container_issue | 5 |
| container_start_page | 758 |
| container_title | Cancer |
| container_volume | 76 |
| creator | Lara, Pedro C. Cuyás, Jose Ma |
| description | Background. The efficacy of squamous cell carcinoma antigen (SCC‐Ag) in laryngeal cancer to predict those patients who will relapse after primary treatment (surgery or radiotherapy) and its utility to detect relapses early and thereby increase salvage rates and cure were assesed.
Methods. Sixty healthy donors and 168 patients with laryngeal cancer were included in this prospective trial. Squamous cell carcinoma antigen was measured at diagnosis in all patients, 24 hours and 1 week after surgery in 113 patients and every 10 Gy of administered dose and 2 weeks after treatment in 49 patients primarily referred to radiotherapy. The marker was determined every 3‐6 months during follow‐up. All patients who relapsed had SCC‐Ag studies before and after salvage treatment.
Results. The selected cut‐off value was 1.5 ngr/ml (mean value in control group, 0.65 4+ 2 standard deviation [0.38]). Seventy‐eight percent of patients with cancer had elevated SCC‐Ag values at diagnosis. Squamous cell carcinoma antigen was statistically related to TNM categories (T, P < 0.04; N, P < 0.05; Stage, P < 0.01). Seventy‐five percent of those patients with previously elevated pretreatment values normalized after treatment. Incomplete surgical resection (P < 0.0001) or persistence of the disease after radiotherapy (P < 0.01) were related to high posttreatment values. Squamous cell carcinoma antigen was elevated in 88% of the patients who relapsed. In 55% of the recurrences, SCC‐Ag was elevated 3 months before pathologic confirmation of relapse. Salvage by surgery or radiotherapy was effective in 70% of the patients. Squamous cell carcinoma antigen posttreatment values were the most important factor in predicting disease free survival (DFS) (P < 0.0001) and overall survival (P < 0.03).
Conclusions. Squamous cell carcinoma antigen is an excellent marker of residual disease after primary treatment that can lead to the addition of other therapeutic procedures (surgery and postoperative radiotherapy). The absence of posttreatment SCC‐Ag is the best predictor of DFS, its presence detects recurrence in early stages, permitting salvage of an increased proportion of patients primarily referred for palliative treatment. |
| doi_str_mv | 10.1002/1097-0142(19950901)76:5<758::AID-CNCR2820760508>3.0.CO;2-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77843089</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77843089</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4958-f3951136c24bf090bb84adc37749026bc137db719f6aab3645946d9ae22b52d03</originalsourceid><addsrcrecordid>eNqVkVuL1DAUx4Mo6-zqRxD6IKIPHU_uzawIa70tLA7ICuLLIU3TmUqbzjYzLPPtTZlxQB8En0Jyfjn8L4S8ozCnAOw1BaNzoIK9pMZIMEBfabWQb7QsFour6_d5-aX8ygoGWoGE4i2fw7xcXrLcPCCz0-eHZAYARS4F__6YnMf4M101k_yMnBWKSar1jNS3a5-NQ-ezocni3c72wy5mzndd5uzo2jD0NrNh2658yNqQbRPe22BXvvdhO33q7LgPK2-7hNXZer8ZNuvTk7PB-fEJedTYLvqnx_OCfPv44bb8nN8sP12XVze5E0YWecONpJQrx0TVJNdVVQhbO661MMBU5SjXdaWpaZS1FVdCGqFqYz1jlWQ18Avy4rB3Mw53Ox-32Ldx8mKDT7ZQ60JwKEwCfxxANw4xjr7Bzdj2STVSwKkCnFLEKUX8XQFqhRJTBYipAvyzAuQIWC6R4bT82VHFrup9fVp9zDzNnx_nNjrbNWPKqI0nLPliRtCE-QN233Z-_18C_6nvrwn_BXR2sHU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77843089</pqid></control><display><type>article</type><title>The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Lara, Pedro C. ; Cuyás, Jose Ma</creator><creatorcontrib>Lara, Pedro C. ; Cuyás, Jose Ma</creatorcontrib><description><![CDATA[Background. The efficacy of squamous cell carcinoma antigen (SCC‐Ag) in laryngeal cancer to predict those patients who will relapse after primary treatment (surgery or radiotherapy) and its utility to detect relapses early and thereby increase salvage rates and cure were assesed.
Methods. Sixty healthy donors and 168 patients with laryngeal cancer were included in this prospective trial. Squamous cell carcinoma antigen was measured at diagnosis in all patients, 24 hours and 1 week after surgery in 113 patients and every 10 Gy of administered dose and 2 weeks after treatment in 49 patients primarily referred to radiotherapy. The marker was determined every 3‐6 months during follow‐up. All patients who relapsed had SCC‐Ag studies before and after salvage treatment.
Results. The selected cut‐off value was 1.5 ngr/ml (mean value in control group, 0.65 4+ 2 standard deviation [0.38]). Seventy‐eight percent of patients with cancer had elevated SCC‐Ag values at diagnosis. Squamous cell carcinoma antigen was statistically related to TNM categories (T, P < 0.04; N, P < 0.05; Stage, P < 0.01). Seventy‐five percent of those patients with previously elevated pretreatment values normalized after treatment. Incomplete surgical resection (P < 0.0001) or persistence of the disease after radiotherapy (P < 0.01) were related to high posttreatment values. Squamous cell carcinoma antigen was elevated in 88% of the patients who relapsed. In 55% of the recurrences, SCC‐Ag was elevated 3 months before pathologic confirmation of relapse. Salvage by surgery or radiotherapy was effective in 70% of the patients. Squamous cell carcinoma antigen posttreatment values were the most important factor in predicting disease free survival (DFS) (P < 0.0001) and overall survival (P < 0.03).
Conclusions. Squamous cell carcinoma antigen is an excellent marker of residual disease after primary treatment that can lead to the addition of other therapeutic procedures (surgery and postoperative radiotherapy). The absence of posttreatment SCC‐Ag is the best predictor of DFS, its presence detects recurrence in early stages, permitting salvage of an increased proportion of patients primarily referred for palliative treatment.]]></description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(19950901)76:5<758::AID-CNCR2820760508>3.0.CO;2-9</identifier><identifier>PMID: 8625177</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Antigens, Neoplasm - analysis ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; cancer of the larynx ; conservative treatment ; Humans ; Hypopharyngeal Neoplasms - diagnosis ; Hypopharyngeal Neoplasms - mortality ; Hypopharyngeal Neoplasms - pathology ; Hypopharyngeal Neoplasms - therapy ; Laryngeal Neoplasms - diagnosis ; Laryngeal Neoplasms - mortality ; Laryngeal Neoplasms - pathology ; Laryngeal Neoplasms - therapy ; Medical sciences ; Middle Aged ; Neoplasm Metastasis - diagnosis ; Neoplasm Recurrence, Local - diagnosis ; Otorhinolaryngology. Stomatology ; Predictive Value of Tests ; Prognosis ; Prospective Studies ; protocols ; Sensitivity and Specificity ; Serpins ; squamous cell carcinoma antigen ; Survival Rate ; Tumors ; Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology</subject><ispartof>Cancer, 1995-09, Vol.76 (5), p.758-764</ispartof><rights>Copyright © 1995 American Cancer Society</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4958-f3951136c24bf090bb84adc37749026bc137db719f6aab3645946d9ae22b52d03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3642941$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8625177$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lara, Pedro C.</creatorcontrib><creatorcontrib>Cuyás, Jose Ma</creatorcontrib><title>The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer</title><title>Cancer</title><addtitle>Cancer</addtitle><description><![CDATA[Background. The efficacy of squamous cell carcinoma antigen (SCC‐Ag) in laryngeal cancer to predict those patients who will relapse after primary treatment (surgery or radiotherapy) and its utility to detect relapses early and thereby increase salvage rates and cure were assesed.
Methods. Sixty healthy donors and 168 patients with laryngeal cancer were included in this prospective trial. Squamous cell carcinoma antigen was measured at diagnosis in all patients, 24 hours and 1 week after surgery in 113 patients and every 10 Gy of administered dose and 2 weeks after treatment in 49 patients primarily referred to radiotherapy. The marker was determined every 3‐6 months during follow‐up. All patients who relapsed had SCC‐Ag studies before and after salvage treatment.
Results. The selected cut‐off value was 1.5 ngr/ml (mean value in control group, 0.65 4+ 2 standard deviation [0.38]). Seventy‐eight percent of patients with cancer had elevated SCC‐Ag values at diagnosis. Squamous cell carcinoma antigen was statistically related to TNM categories (T, P < 0.04; N, P < 0.05; Stage, P < 0.01). Seventy‐five percent of those patients with previously elevated pretreatment values normalized after treatment. Incomplete surgical resection (P < 0.0001) or persistence of the disease after radiotherapy (P < 0.01) were related to high posttreatment values. Squamous cell carcinoma antigen was elevated in 88% of the patients who relapsed. In 55% of the recurrences, SCC‐Ag was elevated 3 months before pathologic confirmation of relapse. Salvage by surgery or radiotherapy was effective in 70% of the patients. Squamous cell carcinoma antigen posttreatment values were the most important factor in predicting disease free survival (DFS) (P < 0.0001) and overall survival (P < 0.03).
Conclusions. Squamous cell carcinoma antigen is an excellent marker of residual disease after primary treatment that can lead to the addition of other therapeutic procedures (surgery and postoperative radiotherapy). The absence of posttreatment SCC‐Ag is the best predictor of DFS, its presence detects recurrence in early stages, permitting salvage of an increased proportion of patients primarily referred for palliative treatment.]]></description><subject>Antigens, Neoplasm - analysis</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>cancer of the larynx</subject><subject>conservative treatment</subject><subject>Humans</subject><subject>Hypopharyngeal Neoplasms - diagnosis</subject><subject>Hypopharyngeal Neoplasms - mortality</subject><subject>Hypopharyngeal Neoplasms - pathology</subject><subject>Hypopharyngeal Neoplasms - therapy</subject><subject>Laryngeal Neoplasms - diagnosis</subject><subject>Laryngeal Neoplasms - mortality</subject><subject>Laryngeal Neoplasms - pathology</subject><subject>Laryngeal Neoplasms - therapy</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis - diagnosis</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Otorhinolaryngology. Stomatology</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>protocols</subject><subject>Sensitivity and Specificity</subject><subject>Serpins</subject><subject>squamous cell carcinoma antigen</subject><subject>Survival Rate</subject><subject>Tumors</subject><subject>Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkVuL1DAUx4Mo6-zqRxD6IKIPHU_uzawIa70tLA7ICuLLIU3TmUqbzjYzLPPtTZlxQB8En0Jyfjn8L4S8ozCnAOw1BaNzoIK9pMZIMEBfabWQb7QsFour6_d5-aX8ygoGWoGE4i2fw7xcXrLcPCCz0-eHZAYARS4F__6YnMf4M101k_yMnBWKSar1jNS3a5-NQ-ezocni3c72wy5mzndd5uzo2jD0NrNh2658yNqQbRPe22BXvvdhO33q7LgPK2-7hNXZer8ZNuvTk7PB-fEJedTYLvqnx_OCfPv44bb8nN8sP12XVze5E0YWecONpJQrx0TVJNdVVQhbO661MMBU5SjXdaWpaZS1FVdCGqFqYz1jlWQ18Avy4rB3Mw53Ox-32Ldx8mKDT7ZQ60JwKEwCfxxANw4xjr7Bzdj2STVSwKkCnFLEKUX8XQFqhRJTBYipAvyzAuQIWC6R4bT82VHFrup9fVp9zDzNnx_nNjrbNWPKqI0nLPliRtCE-QN233Z-_18C_6nvrwn_BXR2sHU</recordid><startdate>19950901</startdate><enddate>19950901</enddate><creator>Lara, Pedro C.</creator><creator>Cuyás, Jose Ma</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19950901</creationdate><title>The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer</title><author>Lara, Pedro C. ; Cuyás, Jose Ma</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4958-f3951136c24bf090bb84adc37749026bc137db719f6aab3645946d9ae22b52d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Antigens, Neoplasm - analysis</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>cancer of the larynx</topic><topic>conservative treatment</topic><topic>Humans</topic><topic>Hypopharyngeal Neoplasms - diagnosis</topic><topic>Hypopharyngeal Neoplasms - mortality</topic><topic>Hypopharyngeal Neoplasms - pathology</topic><topic>Hypopharyngeal Neoplasms - therapy</topic><topic>Laryngeal Neoplasms - diagnosis</topic><topic>Laryngeal Neoplasms - mortality</topic><topic>Laryngeal Neoplasms - pathology</topic><topic>Laryngeal Neoplasms - therapy</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis - diagnosis</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Otorhinolaryngology. Stomatology</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>protocols</topic><topic>Sensitivity and Specificity</topic><topic>Serpins</topic><topic>squamous cell carcinoma antigen</topic><topic>Survival Rate</topic><topic>Tumors</topic><topic>Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lara, Pedro C.</creatorcontrib><creatorcontrib>Cuyás, Jose Ma</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lara, Pedro C.</au><au>Cuyás, Jose Ma</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1995-09-01</date><risdate>1995</risdate><volume>76</volume><issue>5</issue><spage>758</spage><epage>764</epage><pages>758-764</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract><![CDATA[Background. The efficacy of squamous cell carcinoma antigen (SCC‐Ag) in laryngeal cancer to predict those patients who will relapse after primary treatment (surgery or radiotherapy) and its utility to detect relapses early and thereby increase salvage rates and cure were assesed.
Methods. Sixty healthy donors and 168 patients with laryngeal cancer were included in this prospective trial. Squamous cell carcinoma antigen was measured at diagnosis in all patients, 24 hours and 1 week after surgery in 113 patients and every 10 Gy of administered dose and 2 weeks after treatment in 49 patients primarily referred to radiotherapy. The marker was determined every 3‐6 months during follow‐up. All patients who relapsed had SCC‐Ag studies before and after salvage treatment.
Results. The selected cut‐off value was 1.5 ngr/ml (mean value in control group, 0.65 4+ 2 standard deviation [0.38]). Seventy‐eight percent of patients with cancer had elevated SCC‐Ag values at diagnosis. Squamous cell carcinoma antigen was statistically related to TNM categories (T, P < 0.04; N, P < 0.05; Stage, P < 0.01). Seventy‐five percent of those patients with previously elevated pretreatment values normalized after treatment. Incomplete surgical resection (P < 0.0001) or persistence of the disease after radiotherapy (P < 0.01) were related to high posttreatment values. Squamous cell carcinoma antigen was elevated in 88% of the patients who relapsed. In 55% of the recurrences, SCC‐Ag was elevated 3 months before pathologic confirmation of relapse. Salvage by surgery or radiotherapy was effective in 70% of the patients. Squamous cell carcinoma antigen posttreatment values were the most important factor in predicting disease free survival (DFS) (P < 0.0001) and overall survival (P < 0.03).
Conclusions. Squamous cell carcinoma antigen is an excellent marker of residual disease after primary treatment that can lead to the addition of other therapeutic procedures (surgery and postoperative radiotherapy). The absence of posttreatment SCC‐Ag is the best predictor of DFS, its presence detects recurrence in early stages, permitting salvage of an increased proportion of patients primarily referred for palliative treatment.]]></abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>8625177</pmid><doi>10.1002/1097-0142(19950901)76:5<758::AID-CNCR2820760508>3.0.CO;2-9</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 1995-09, Vol.76 (5), p.758-764 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77843089 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Antigens, Neoplasm - analysis Biological and medical sciences Biomarkers, Tumor - analysis cancer of the larynx conservative treatment Humans Hypopharyngeal Neoplasms - diagnosis Hypopharyngeal Neoplasms - mortality Hypopharyngeal Neoplasms - pathology Hypopharyngeal Neoplasms - therapy Laryngeal Neoplasms - diagnosis Laryngeal Neoplasms - mortality Laryngeal Neoplasms - pathology Laryngeal Neoplasms - therapy Medical sciences Middle Aged Neoplasm Metastasis - diagnosis Neoplasm Recurrence, Local - diagnosis Otorhinolaryngology. Stomatology Predictive Value of Tests Prognosis Prospective Studies protocols Sensitivity and Specificity Serpins squamous cell carcinoma antigen Survival Rate Tumors Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology |
| title | The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T18%3A46%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20squamous%20cell%20carcinoma%20antigen%20in%20the%20management%20of%20laryngeal%20and%20hypopharyngeal%20cancer&rft.jtitle=Cancer&rft.au=Lara,%20Pedro%20C.&rft.date=1995-09-01&rft.volume=76&rft.issue=5&rft.spage=758&rft.epage=764&rft.pages=758-764&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/1097-0142(19950901)76:5%3C758::AID-CNCR2820760508%3E3.0.CO;2-9&rft_dat=%3Cproquest_cross%3E77843089%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77843089&rft_id=info:pmid/8625177&rfr_iscdi=true |